Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, March 13, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Oren Livnat Maintained (ANIP) at Strong Buy with Increased Target to $53 on, Mar 13th, 2023
Oren Livnat of HC Wainwright & Co., Maintained "ANI Pharmaceuticals, Inc." (ANIP) at Strong Buy with Increased Target from $50 to $53 on, Mar 13th, 2023.
Oren has made no other calls on ANIP in the last 4 months.
There is 1 other peer that has a rating on ANIP. Out of the 1 peers that are also analyzing ANIP, 0 agree with Oren's Rating of Hold.
This is the rating of the analyst that currently disagrees with Oren
- Vamil Divan of "Guggenheim" Initiated at Strong Buy and Held Target at $55 on, Wednesday, March 1st, 2023
